Physician profile
Sidney Lerfald
NPI 1932163979
$14,435.41
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $8,375.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $4,959.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $178.62 | 2019 | |
| Allergan, INC. | $165.28 | 2019 | |
| Amgen INC. | $150.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $149.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $88.53 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.40 | 2019 | |
| Lundbeck LLC | $74.26 | 2019 | |
| Shire North American Group INC | $44.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.95 | 2019 | |
| Bausch Health US, LLC | $15.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Lerfald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.